carmustine has been researched along with Rhabdomyosarcoma in 7 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Rhabdomyosarcoma: A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous investigations have revealed that the human TE-671 MR human rhabdomyosarcoma xenograft selected in vivo for melphalan resistance (M." | 7.69 | Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. ( Ali-Osman, F; Bigner, DD; Colvin, OM; Dolan, ME; Friedman, HS; Griffith, OW; Kaufmann, SH; Moschel, RC; Schold, SC, 1994) |
| "Previous investigations have revealed that the human TE-671 MR human rhabdomyosarcoma xenograft selected in vivo for melphalan resistance (M." | 3.69 | Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. ( Ali-Osman, F; Bigner, DD; Colvin, OM; Dolan, ME; Friedman, HS; Griffith, OW; Kaufmann, SH; Moschel, RC; Schold, SC, 1994) |
| "Our previous studies exploring melphalan resistance in the human rhabdomyosarcoma xenograft TE-671 MR revealed elevation of DNA polymerase-alpha and DNA polymerase-beta." | 3.69 | Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta. ( Ali-Osman, F; Bigner, DD; Elion, GB; Friedman, HS; Keir, S; Marcelli, S; Moynihan, K, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rivero-Garvía, M | 1 |
| Márquez-Rivas, J | 1 |
| Rivas, E | 1 |
| Medina-López, D | 1 |
| Quiroga-Cantero, E | 1 |
| Aleĭnikova, OV | 1 |
| Strongin, IuS | 1 |
| Pochetukhin, KV | 1 |
| Bacolod, MD | 1 |
| Johnson, SP | 1 |
| Ali-Osman, F | 3 |
| Modrich, P | 1 |
| Bullock, NS | 1 |
| Colvin, OM | 2 |
| Bigner, DD | 3 |
| Friedman, HS | 3 |
| Dolan, ME | 1 |
| Kaufmann, SH | 1 |
| Griffith, OW | 1 |
| Moschel, RC | 1 |
| Schold, SC | 1 |
| Moynihan, K | 1 |
| Elion, GB | 1 |
| Marcelli, S | 1 |
| Keir, S | 1 |
| Slavik, M | 1 |
| Smith, DG | 1 |
| Brent, TP | 1 |
1 trial available for carmustine and Rhabdomyosarcoma
| Article | Year |
|---|---|
Clinical studies with DTIC (NSC-45388) in various malignancies.
Topics: Adult; Carmustine; Child; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Comb | 1976 |
6 other studies available for carmustine and Rhabdomyosarcoma
| Article | Year |
|---|---|
Primary cerebral radiotherapy-induced rhabdomyosarcoma: treatment with intraoperative carmustine implants.
Topics: Brain Neoplasms; Carmustine; Child; Female; Humans; Intraoperative Period; Neoplasms, Radiation-Indu | 2013 |
[High-dose chemotherapy with autologous bone marrow transplantation in children with high-risk malignant neoformations].
Topics: Adolescent; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo | 2002 |
Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.
Topics: Amino Acid Sequence; Apoptosis; Carmustine; Cloning, Molecular; Dose-Response Relationship, Drug; Do | 2002 |
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Camptothecin; Carmustine; DNA Polymeras | 1994 |
Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Aphidicolin; Carmustine; DNA Poly | 1996 |
Response of cultured human cell lines from rhabdomyosarcoma xenografts to treatment with chloroethylnitrosoureas.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Division; Cell Survival; Drug Screening Assays, Ant | 1989 |